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Objective: To report a case of Aspergillus flavus malignant otitis externa, successfully treated
with antifungal agents, surgical debridement, and hyperbaric oxygen treatment.
Patient: The case was a 77-year-old man with non-insulin dependent diabetes mellitus, who
presented with otalgia and purulent otorrhea. Intervention was with surgical debridement,
antifungal agents, and hyperbaric oxygen treatment. The main outcome measures were radi-
ological and histological findings.
Conclusions: A. flavus is a rare cause of malignant otitis externa. Aggressive treatment should
include surgical debridement, with appropriate antifungal agents and hyperbaric oxygen therapy.
Crown Copyright# 2008 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.Introduction
Malignant otitis externa (MOE) is a rare, potentially fatal
invasive infection of the external auditory canal. Spread to
the surrounding tissues can lead to extensive osteomyelitis
and cranial neuropathies. The condition is usually seen in
elderly diabetics, but it is also increasingly seen in patients
who are immunocompromised. Patients typically present
with severe otalgia and otorrhea, which is unresponsive to
topical therapy, but can also present with headache or
cranial nerve neuropathies.
The majority of cases (>98%) are due to Pseudomonas
aeruginosa1 and the primary therapy for MOE is anti-pseu-
domonal antibiotics. Prior to the development of more
potent and less toxic antibiotics, surgical debridement was* Corresponding author. Tel.: +618 9224 2244; fax: +618 9383 9528.
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1201-9712/$32.00. Crown Copyright# 2008 Published by Elsevier Ltd on be
doi:10.1016/j.ijid.2008.03.003the mainstay of treatment. Surgical management is now
mainly diagnostic and constitutes an adjunctive therapy.
Fungal cases of MOE are rare, with the most common
causative organism being Aspergillus fumigatus. In the
reported cases of fungal MOE,2,3 various management stra-
tegies were employed to treat the disease, with mixed out-
comes. The following case is of MOE due to Aspergillus flavus,
which was successfully treated with surgical debridement,
aggressive antifungal agents, and hyperbaric oxygen therapy.
Case report
A 77-year-old man presented with a 5-week history of right-
sided otalgia, radiating to the temporal fossa and lower jaw.
He complained of aural fullness three days prior to admission.
He had a past medical history of non-insulin-dependent
diabetes mellitus, hypertension, and gout. On examination
he had a grossly edematous right external auditory canal,half of International Society for Infectious Diseases. All rights reserved.
Figure 1 Magnetic resonance image showing skull base osteo-
myelitis.
Fungal malignant otitis externa 551with green discharge. The tympanic membrane was erythe-
matous and bulging posterosuperiorly. An audiogram demon-
strated bilateral, symmetrical, moderately severe high tone
sensori-neural hearing loss.
The ear was swabbed and sent for microscopy, culture,
and sensitivity. He was then started on empirical intravenous
ticarcillin/clavulanate and oral ciprofloxacin. His symptoms
worsened with increasing pain and he became more systemi-
cally unwell. Superficial swabs grew Candida parapsilosis and
A. flavus.
Magnetic resonance imaging (MRI) scans showed edema
and enhancement in the right external canal consistent with
otitis externa, with enhancing soft tissue present in the
middle ear cleft and ill defined subtemporal enhancing tissue
and edema (Figure 1). There was evidence of temporal bone
osteomyelitis and diffuse infra-temporal osteomyelitis, with
overlying dural thickening. A gallium scan at this time also
reported that there was increased activity in the right tem-
poral bone, especially at the petrous part, consistent with
our clinical impression of MOE.
The C-reactive protein (CRP) levels remained between 60
and 70 mg/l and the erythrocyte sedimentation rate (ESR)
above 100 mm/h. His other blood results were within refer-
ence ranges. Clinically, he had persistent otalgia and had
developed a right grade 4 House—Brackmann facial nerve
palsy, with other cranial nerves intact.
Given these findings, and the worsening symptoms, a right
cortical mastoidectomy was performed for debridement and
collection of deep tissue biopsies. These deep tissue biopsies
later isolated A. flavus.He was then commenced on intravenous voriconazole and
caspofungin. Minimum inhibitory concentrations (MICs) were
not obtained for the isolate. Voriconazole levels were main-
tained at appropriate levels during this time. His blood sugar
levels weremanaged appropriately. Hyperbaric oxygen treat-
ment was started. This regime consisted of 30 sessions of
100% oxygen at a pressure of 2.4 atmospheres. His otalgia
improved significantly and his facial nerve palsy began to
resolve.
A repeat gallium scan at this time showed a reduction in
gallium uptake in the temporal bone as compared to the
initial study. Serial blood tests showed declining CRP levels
and slowly declining ESR levels. The voriconazole was con-
tinued at 200 mg twice daily.
After an eight-week admission, the patient no longer
complained of otalgia, and the right ear canal was clear of
debris and his facial nerve had completely resolved. He was
discharged from hospital with oral voriconazole 200 mg twice
daily, with follow-up after hyperbaric treatment as an out-
patient. Serial blood tests were continued, and at six weeks
after discharge, the ESR and CRP levels returned to normal,
and a repeat gallium scan at this time showed a further
reduction in activity in the temporal bone. The voriconazole
was ceased and the patient remains free of disease after 2
years.Discussion
Fungal MOE is rare, and is most often due to A. fumigatus, but
cases involving A. flavus and other species have also been
reported.2 Aspergillus are ubiquitous saprophytic moulds,
commonly found on decaying material around the world.
Aspergillus also produce a variety of compounds that can
contribute to their pathogenicity, such as various proteases,
aflatoxin, and phospholipases, and grow at a rapid rate when
around 37 8C. The first line of defense against aspergillosis is
the macrophages, which attach, ingest, and kill the conidia.4
The hyphae are damaged and killed extracellularly by neu-
trophils, with some contribution from monocytes and macro-
phages.
A. flavus causes a broad spectrum of disease in humans,
and this can range from hypersensitivity reactions to osteo-
myelitis following trauma or inoculation.5 It can be more
difficult to treat due to more resistance to antifungal agents,
and has been shown to be more virulent than other Asper-
gillus species, including A. fumigatus. Interestingly, it has
been noted that infections due to this particular fungus are
more important in dry and hot climates, such as those
experienced from where this case was reported. While MICs
were not performed in this case, the patient made a good
clinical recovery while being on a combination of voricona-
zole and caspofungin.
In diseased tissue, perfusion is commonly poor, resulting in
low oxygen tension in these tissues. In tissues infected by
Aspergillus, oxygen tension is reduced due to the fungal
invasion of blood vessels, causing occlusion, thrombosis,
and hypoxia.6 Hyperbaric oxygen therapy (HBOT) greatly
increases the oxygen carried in blood, so that hypoxic tissue
can be returned to normal oxygen tension, or higher. A
hyperoxic state also promotes the laying of collagen and
angiogenesis, promoting soft tissue and bone healing.
552 S.S. Ling, C. SaderHBOT has been studied in a variety of conditions where
optimization of wound healing and microorganism killing is
vital, and is used as adjunctive therapy in refractory osteo-
myelitis.7 In refractory osteomyelitis, treatment failures with
antibiotics and surgical debridement are often associatedwith
systemic host and local immunocompromised factors. In MOE,
treatment failure can lead to multiple cranial neuropathies
and intracranial extension of the infection. Davis et al.8 have
suggested that HBOT be recommended in more advanced
stages of disease, where there is skull base osteomyelitis
and intracranial extension. Shupaket al.9 suggested thatHBOT
be offered routinely to all cases of MOE.
The clinical picture of fungal MOE is very similar to that
caused by bacteria. Often the diagnosis of fungal MOE is
delayed, because treatment is usually initiated against Pseu-
domonas. As occurred in this case, anti-pseudomonal agents
were started initially, but the lack of clinical response, and
the worsening of symptoms, made the diagnosis of a bacterial
cause less likely. In addition, the pathogenicity of Aspergillus
may be enhanced by disruption of the normal bacterial flora
in the ear, either by recent or concurrent broad-spectrum
antibiotics.10
Conclusions
Cases of fungal MOE caused by A. flavus are rare, with A.
fumigatus much more common as the fungal pathogen. The
nature of A. flavus can make treatment difficult, as it is more
virulent than A. fumigatus and has higher resistance to
antifungal treatment. The patient reported may have been
at a higher risk due to factors such as elderly age and diabetes
mellitus. In treating such infections, it is important to have ahigh index of suspicion and to institute early and aggressive
medical and surgical treatment. There may be a role for
HBOT, but this may depend on the availability and accessi-
bility of such treatments at various institutions.
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